Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Clin Imaging. 2016 Jun 13;40(5):1047–1054. doi: 10.1016/j.clinimag.2016.06.002

Fig. 2.

Fig. 2

Hematoxylin-eosin stained slides of representative fibroadenomas with original magnification ×100 and their corresponding ADC values:

A, 65-year-old woman with personal history of right-breast invasive ductal carcinoma, status post lumpectomy with an MRI-detected fibroadenoma in the left breast exhibiting no epithelial hyperplasia, low stromal cellularity, no immune cell infiltration and dense stroma.

B, 49-year-old woman with personal history of right-breast invasive ductal carcinoma, status post lumpectomy, with an MRI-detected fibroadenoma in the left breast exhibiting epithelial hyperplasia, high stromal cellularity, no immune cell infiltration and dense stroma.

C, 48-year-old woman with personal history of left-breast lobular carcinoma in situ, status post lumpectomy, with an MRI-detected fibroadenoma in the right breast exhibiting epithelial hyperplasia, low stromal cellularity, no immune cell infiltration and dense stroma.

D, 35-year-old woman with personal history of left-breast ductal carcinoma in situ, status post lumpectomy, with an MRI-detected fibroadenoma in the right breast exhibiting epithelial hyperplasia, high stromal cellularity, no immune cell infiltration and dense stroma.

E, 35-year-old woman undergoing neoadjuvant chemotherapy for right breast inflammatory ductal carcinoma, with an MRI-detected fibroadenoma in the left breast exhibiting no epithelial hyperplasia, low stromal cellularity, no immune cell infiltration and sparse stroma.

F, 40-year-old high-risk woman with an MRI-detected fibroadenoma in the left breast exhibiting epithelial hyperplasia, low stromal cellularity, immune cell infiltration and sparse stroma.